中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (6): 481-485,489.doi: 10.12007/j.issn.0258‐4646.2018.06.001

• 论著 •    下一篇

miR-152靶向Mirk/Dyrk1B调控人卵巢癌干细胞紫杉醇敏感性的研究

倪莎, 郭绮璇, 汪玲, 欧阳玲, 周欣   

  1. 中国医科大学附属盛京医院妇产科, 沈阳 110004
  • 收稿日期:2018-03-14 出版日期:2018-06-30 发布日期:2018-05-29
  • 通讯作者: 周欣 E-mail:drzhouxin@163.com
  • 作者简介:倪莎(1986-),女,医师,博士.
  • 基金资助:
    国家自然科学基金(81101990);辽宁省教育厅重点实验室项目(LS201602);沈阳市科技创新专项资金(F15-139-9-34)

miR-152 Regulates the Sensitivity of Human Ovarian Cancer Stem Cells to Paclitaxel by Targeting Mirk/Dyrk1B

NI Sha, GUO Qixuan, WANG Ling, OUYANG Ling, ZHOU Xin   

  1. Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang 110004, China
  • Received:2018-03-14 Online:2018-06-30 Published:2018-05-29

摘要: 目的 探讨miR-152对人卵巢癌干细胞球紫杉醇敏感性的影响及可能的机制。方法 分离培养人卵巢癌干细胞球,构建miR-152的差异表达体系,用CCK-8法检测紫杉醇作用下卵巢癌干细胞存活率;用荧光素酶报告基因系统鉴定miR-152与Mirk/Dyrk1B的靶向调控关系;蛋白印迹检测改变miR-152表达水平对Mirk/Dyrk1B及耐药相关蛋白的影响。结果 过表达miR-152或降低Mirk/Dyrk1B表达水平可增强人卵巢癌干细胞球对紫杉醇的敏感性。miR-152能够特异性结合Mirk/Dyrk1B 3'-UTR区域。miR-152与Mirk/Dyrk1B差异表达影响人卵巢癌干细胞球耐药相关蛋白的表达水平。结论 miR-152可能通过靶向调节Mirk/Dyrk1B影响人卵巢癌干细胞球对紫杉醇的敏感性。

关键词: miR-152, Mirk/Dyrk1B, 卵巢癌, 肿瘤干细胞, 紫杉醇

Abstract: Objective To investigate the influence of miR-152 on the sensitivity of human ovarian cancer stem cells to paclitaxel and to understand the underlying mechanism. Methods The ovarian cancer stem cell spheres were isolated from the OVCAR3 cell line. miR-152 mimics were transfected into the ovarian cancer stem cells by lipofectamine 2000 and the viability of these cells after treatment with paclitaxel was examined by the CCK-8 assay. The regulatory relationship between miR-152 and Mirk/Dyrk1B was investigated by the luciferase reporter assay. The protein levels of Mirk/Dyrk1B and other drug resistance-related proteins were analyzed by Western blotting. Results Alteration of miR-152 or Mirk/Dyrk1B could influence the sensitivity of ovarian cancer stem cells to paclitaxel and regulate the expression of drug resistance-related proteins. miR-152 could bind to the 3'-UTR of Mirk/Dyrk1B mRNA. Conclusion miR-152 regulates the sensitivity of human ovarian cancer stem cells to paclitaxel by targeting Mirk/Dyrk1B.

Key words: miR-152, Mirk/Dyrk1B, ovarian cancer, tumor stem cell, paclitaxel

中图分类号: 

  • R711.75
[1] LAPIDOT T,SIRARD C,VORMOOR J,et al. A cell initiating human a-cute myeloid leukaemia after transplantation into SCID mice[J]. Nature,1994,367(6464):645-648. DOI:10.1038/367645a0.
[2] REYA T,MORRISON SJ,CLARKE MF,et al. Stem cells,cancer, and cancer stem cells[J]. Nature,2001,414(6859):105-111. DOI:10.1038/35102167.
[3] ZHANG YJ,LIU XC,DU J,et al. miR-152 regulates metastases of non-small cell lung cancer cells by targeting neuropilin-1[J]. Int J Clin Exp Pathol,2015,8(11):14235-14240.
[4] ZHAI R,KAN X,WANG B,et al. miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151[J]. Tumour Biol, 2014,35(11):11367-11373. DOI:10.1007/s13277-014-2471-2.
[5] THEODORE SC,DAVIS M,ZHAO F,et al. MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase1[J]. Oncotarget,2014,5(11):3512-3525. DOI:10.18632/oncotarget.1953.
[6] HUANG H,HU M,LI P,et al. miR-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT[J]. Tumour Biol,2015,36(2):921-928. DOI:10.1007/s13277-014-2719-x.
[7] ZHOU X,ZHAO F,WANG ZN,et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation[J]. Oncol Rep,2012,27(2):447-454. DOI:10.3892/or.2011.1482.
[8] LI LW,XIAO HQ,MA R,et al. miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3[J]. Int J Mol Med,2018,41(3):1529-1535. DOI:10.3892/ijmm.2017.3324.
[9] QIN W,XIE W,HE Q,et al.MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1[J]. Exp Ther Med,2018,15(2):1672-1679. DOI:10.3892/etm.2017.5529.
[10] HE J,YU JJ,XU Q,et al. ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy[J]. Autophagy,2015,11(2):373-384. DOI:10.1080/15548627.2015. 1009781.
[11] LIU L,ZOU J,WANG Q,et al. Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer[J]. Tumour Biol,2014,35(8):7713-7717. DOI:10.1007/s13277-014-1970-5.
[12] REAM L,NORRIS L,SAADEH FA,et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease[J]. Cancer Lett,2015, (28) 356:628-636. DOI:10.1016/j.canlet.2014.10.010.
[13] LEDER S,WEBER Y,ALTAFAJ X,et al. Cloning and characterization of Dyrk1B,a novel member of the DYRK family of protein kinases[J]. Biochem Biophys Res Commun,1999(2):474-479. DOI:10.1006/bbrc. 1998.9967.
[14] BAGGA S,BRACHT J,HUNTER S,et al. Regulation by let -7 and lin-4 miRNAs results in target mRNA degradation[J]. Cell,2005, 122(4):553-563. DOI:10.1016/j.cell.2005.07.031.
[15] XIANG Y,MA N,WANG D,et al. miR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly:a novel epigenetic therapy independent of decitabine[J]. Oncogene,2014,33(3):378-386. DOI:10.1038/onc.2012.575.
[16] DENG X,EWTON DZ,LI S,et al. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma[J]. Cancer Res,2006,66(8):4149-4158. DOI:10.1158/0008-5472.CAN-05-3089.
[17] GAO J,ZHENG Z,RAWAL B,et al. Mirk/Dyrk1B,a novel therapeutic target mediates cell survival in non-small cell lung cancer cells[J]. Cancer Biol Ther,2009,8(17):1671-1679. DOI:10.4161/cbt.8.17.9322.
[18] KELLAND IR. Preclinical perspectives on platinum resistance[J]. Drug,2000,59(4):1-8. DOI:10.2165/00003495-200059004-00001.
[19] DENG X,FRIEDMAN E. Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells[J]. Genes Cancer,2014,5(9/10):337-347. DOI:10.18632/genesandcancer.29.
[20] JING H,EILEEN F. Depleting Mirk/Dyrk1B kinase increases cisplatin toxicity in ovarian cancer cells[J]. Genes Cancer,2010,1(8):803-811. DOI:10. 1177/1947601910377644.
[21] JING H,HOLLY D,FRIEDMAN EA. Ovarian cancer cells,not normal cells,are damaged by Mirk/Dyrk1B/Dyrk1B kinase Inhibition[J]. Int J Cancer,2013,132(10):2258-2269. DOI:10.1002/ijc.27917.
[22] TIBERIO P,CAVADINI E,ABOLAFIO G,et al. 4-oxo-N-(4-hydroxyphenyl) retinamide:two independent ways to kill cancer cells[J]. PLoS One,2010,5(10):e13362. DOI:10.1371/journal. pone.0013362.
[23] SINGH R,DHANYAMRAJU PK,LAUTH M. DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway[J]. Oncotarget,2017,8(1):833-845. DOI:10.18632/oncotarget. 13662.
[1] 刘藤藤, 褚达明. 卵巢癌根治术后24 h进流食对患者胃肠功能恢复的影响[J]. 中国医科大学学报, 2018, 47(2): 187-189.
[2] 窦磊, 庞晓燕, 李奇, 尚海, 张颐. 去酰基化ghrelin抑制上皮性卵巢癌细胞的增殖[J]. 中国医科大学学报, 2018, 47(12): 1102-1106.
[3] 王宁,倪莎,周欣. 卡铂短期诱导人卵巢癌类干细胞的分离及初步鉴定[J]. 中国医科大学学报, 2017, 46(8): 713-719.
[4] 杨大磊,毕芳芳,于大海. TNFAIP8 在卵巢癌中的表达及对卵巢癌细胞增殖的影响[J]. 中国医科大学学报, 2016, 45(6): 526-530.
[5] 李达,毕芳芳,杨清. BRCA1在不同化疗敏感性浆液性卵巢癌中的表达及表观遗传学调节机制[J]. 中国医科大学学报, 2016, 45(5): 385-388.
[6] 孟琳,王天一,李晓曦,马萍. miR?206/miR?1对乳腺癌干细胞增殖的影响及作用机制[J]. 中国医科大学学报, 2015, 44(5): 394-399.
[7] 庞晓燕,张颐,孟祥凯,王化丽. 血小板增多对上皮性卵巢癌预后的影响[J]. 中国医科大学学报, 2014, 43(9): 798-801.
[8] 胡琰洁,赵丽雅,张颐. 卵巢癌合并皮肌炎2例回顾分析及文献复习[J]. 中国医科大学学报, 2014, 43(4): 363-364.
[9] 周万,周向东,尤列?皮尔曼,维克多?科罗索夫. OGR1籍ERK信号通路参与酸性微环境致气道上皮细胞黏蛋白5AC表达[J]. 中国医科大学学报, 2014, 43(2): 122-126.
[10] 刘贵鹏,王爽,张春梅. 催乳素对顺铂诱导卵巢癌细胞凋亡过程的抑制作用[J]. 中国医科大学学报, 2013, 42(5): 447-450.
[11] 方媛媛,杜强,王秀霞,张淑兰. δ-catenin促进卵巢癌细胞的增殖和侵袭[J]. 中国医科大学学报, 2013, 42(4): 334-338.
[12] 刘为英,高沁怡,李亚明,武昕. 18F-FDGPET诊断卵巢癌转移和复发的价值[J]. 中国医科大学学报, 2013, 42(4): 366-368.
[13] 吕红伟,马晓欣,柯孝瑜,李艳霞. 多西他赛对人子宫内膜腺癌Ishikawa细胞凋亡诱导的实验研究[J]. 中国医科大学学报, 2012, 41(8): 716-718.
[14] 李正红 郭科军 薛晖. 新辅助化疗治疗晚期卵巢癌的临床疗效评价[J]. 中国医科大学学报, 2012, 41(7): 645-649.
[15] 王文双, 杨兴升, 马先莹, . Twist介导的上皮间质转化在卵巢癌组织中的作用[J]. 中国医科大学学报, 2012, 41(2): 175-177.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA